Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 29:11:503-513.
doi: 10.2147/JBM.S285647. eCollection 2020.

Clinical Usefulness of Furosemide to Prevent Volume Overload Among Children and Young Adults with Transfusion-Dependent Thalassemia: A Randomized, Open-Label, Crossover Study

Apichat Photia  1 , Chanchai Traivaree  1 , Chalinee Monsereenusorn  1 , Piyarat Simthamnimit  2 , Piya Rujkijyanont  1
Affiliations

Clinical Usefulness of Furosemide to Prevent Volume Overload Among Children and Young Adults with Transfusion-Dependent Thalassemia: A Randomized, Open-Label, Crossover Study

Apichat Photia et al. J Blood Med. .

Abstract

Purpose: Red blood cell transfusion is a key element of treatment among patients with transfusion-dependent thalassemia (TDT). Volume overload and HCC syndrome (hypertension, convulsion, and intracranial hemorrhage) are fatal complications related to transfusion. Furosemide has been widely used to prevent hypertension secondary to volume overload with unclear supportive evidence. This study aimed to evaluate the efficacy of furosemide to prevent volume overload among children and young adults diagnosed with TDT.

Methods: Patients diagnosed with TDT were enrolled and randomized to receive either furosemide pretransfusion or no furosemide pretransfusion. After 3 weeks to 4 months of wash-out periods, those patients underwent the alternate regimens as per crossover design of the study. Clinical and laboratory parameters including blood pressure and NT-proBNP levels were measured before and after each transfusion. The difference of those parameters between two randomized groups and their potential associated factors were analyzed.

Results: In all, 30 patients undergoing 60 red blood cell transfusions were enrolled in the study. All were randomized and crossover was designed as receiving and not receiving furosemide pretransfusion. No transfusion reactions, symptoms of volume overload and HCC syndrome were observed. No statistically significant correlation was found between pretransfusion furosemide and the difference between pre- and posttransfusion systolic blood pressure (2 mmHg systolic blood pressure difference in pretransfusion furosemide and 1.5 mmHg in no pretransfusion furosemide; p-value = 0.721), as well as between pretransfusion furosemide and the difference between pre- and posttransfusion NT-proBNP levels (-3.8 pg/mL NT-proBNP level difference in pretransfusion furosemide and -2.4 pg/mL in no pretransfusion furosemide; p-value = 0.490). No significant correlation was also observed even in selected patients with high NT-proBNP levels (p-value = 0.262). Associated factors affecting the difference between pre- and posttransfusion NT-proBNP levels were analyzed, and none of those were affected concerning the difference in the levels.

Conclusion: Furosemide has been included in standard transfusion guidelines in many institutions. Our study provided important evidence of the unnecessary use of the drug in preventing volume overload particularly in pediatric and young adult patients with TDT.

Thai clinical trials registry tctr number: TCTR20180209001. Registered 6 February 2018, https://www.clinicaltrials.in.th/.

Keywords: NT-proBNP; furosemide; thalassemia; transfusion; volume overload.

PubMed Disclaimer

Conflict of interest statement

All authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Difference of pre- and posttransfusion NT-proBNP levels in patients who received furosemide prior to red blood cell transfusion compared to those who did not receive furosemide prior to transfusion.
Figure 3
Figure 3
Pretransfusion and posttransfusion NT-proBNP levels in patients with high NT-proBNP levels (>129 pg/mL) who received furosemide prior to red blood cell transfusion compared to those who did not receive furosemide prior to transfusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am. 2013;60(6):1383–1391. doi:10.1016/j.pcl.2013.08.008 - DOI - PubMed
    1. Marengo-Rowe AJ. The thalassemias and related disorders. Proc (Bayl Univ Med Cent). 2007;20(1):27–31. doi:10.1080/08998280.2007.11928230 - DOI - PMC - PubMed
    1. Baldini M. Thalassemia major: the present and the future. N Am J Med Sci. 2012;4(3):145–146. - PMC - PubMed
    1. Olivieri NF, Brittenham GM. Management of the thalassemias. Cold Spring Harb Perspect Med. 2013;3(6):a011767–a011767. doi:10.1101/cshperspect.a011767 - DOI - PMC - PubMed
    1. Chonat S, Quinn CT. Current standards of care and long term outcomes for thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:59–87. - PMC - PubMed